Acute Lymphoblastic Leukemia
The latest news, research, and perspectives in acute lymphoblastic leukemia (ALL). The most common type of leukemia in children, ALL develops when bone marrow produces a large number of immature lymphoblasts that grow quickly and replace normal cells in the bone marrow.
Advertisement
Researchers retrospectively analyzed treatment outcomes of 69 patients with relapsed or refractory CRLF2-rearranged B-ALL.
Low hypodiploidy “defines a rare subtype” of B-cell ALL with a “dismal outcome.”
The single-center study was conducted to address gaps in knowledge surrounding minority-predominant populations of patients.
Dr. Jabbour presented data from the study at the Eleventh Annual Meeting of SOHO.
The award is the society’s “most prestigious award" and “serves to honor those that have been pioneers in their work."
This single-center retrospective study looked at outcomes from 18 patients with AML treated with venetoclax plus an HMA.
Advertisement
The study included 59 patients with T-ALL with a median age of 20 at diagnosis.
September is always an exciting time for SOHO members as the month brings the Annual Meeting in Houston, Texas.
Investigators studied mechanisms of resistance to BH3 mimetics to “develop rational combination strategies" for T-cell ALL.
The researchers reported that 46.7% of patients had a BMI in the overweight or obese range.
Induction chemotherapy failure occurred in 10.3% of cases and was significantly associated with increasing age.
Researchers found there are three transcriptomic subtypes of BCR-ABL1 lymphoblastic leukemia.
The study included 30 patients younger than one year who had newly diagnosed KMT2A-rearranged ALL.
EMA CHMP adopted a positive opinion recommending the marketing authorization of JZP458.
From Houston, Texas, to Beirut, Lebanon, the SOHO global community continues to grow thanks to its Ambassador Program.
The study included older patients with newly diagnosed Ph-negative CD22-positive B-lineage ALL.
The study showed that the infusion of obe-cel resulted in very low rates of Grade 3 or higher CRS and ICANS.
The US FDA previously granted breakthrough therapy and priority review designations to blinatumomab.
Blood Cancers Today Associate Elias Jabbour, MD, gives an update from the 2023 EHA Congress.
We went from survival of 10% to 90% and from full-fledged chemotherapy and transplant to a chemotherapy-free regimen.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.